0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.33% SODIUM CHLORIDE INJECTION USP 330 MG / 100 ML
SODIUM CHLORIDE : 330 MG / 100 ML DEXTROSE : 5 G / 100 ML POTASSIUM CHLORIDE : 150 MG / 100 ML · DIN 01931601 · B. BRAUN MEDICAL INC
Health Canada status: CANCELLED POST MARKET
What is 0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.33% SODIUM CHLORIDE INJECTION USP?
0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.33% SODIUM CHLORIDE INJECTION USP 330 MG / 100 ML contains SODIUM CHLORIDE : 330 MG / 100 ML DEXTROSE : 5 G / 100 ML POTASSIUM CHLORIDE : 150 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 01931601, held by B. BRAUN MEDICAL INC, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 23-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is 0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.33% SODIUM CHLORIDE INJECTION USP called?
The same molecule, ELECTROLYTES WITH CARBOHYDRATES, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ADDAMEL AMP. | Latin | Saudi Arabia |
| Hypertonic | Latin | Iceland |
| Ringer lactat Hartmann | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 01931601 |
|---|---|
| Brand name | 0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.33% SODIUM CHLORIDE INJECTION USP |
| Generic / active ingredient | SODIUM CHLORIDE : 330 MG / 100 ML DEXTROSE : 5 G / 100 ML POTASSIUM CHLORIDE : 150 MG / 100 ML |
| Manufacturer | B. BRAUN MEDICAL INC |
| Strength | 330 MG / 100 ML |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BB02 ELECTROLYTES WITH CARBOHYDRATES |
| AHFS class | 40:12.00 ; 40:20.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 23-Jul-2018 |
| Original market date | 1998-09-03 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 01931601 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1931601 |
| Brand name | 0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.33% SODIUM CHLORIDE INJECTION USP |
| Active ingredient / INN | SODIUM CHLORIDE : 330 MG / 100 ML DEXTROSE : 5 G / 100 ML POTASSIUM CHLORIDE : 150 MG / 100 ML |
| ATC code | B05BB02 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05 |
| AHFS class | 40:12.00 ; 40:20.00 |
| Health Canada schedule | Ethical |
| Biosimilar biologic | No |
| Market authorization holder | B. BRAUN MEDICAL INC |
Which pack is which?
| Strength on the label | 330 MG / 100 ML |
|---|---|
| Dosage form | LIQUID |
| Route | INTRAVENOUS |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
What can be used instead?
Other Canadian products sharing ATC code B05BB02 ELECTROLYTES WITH CARBOHYDRATES. 17 of 70 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| (20 MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP | 3.3 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00438014 |
| (20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP | 150 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00786292 |
| (20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP | 150 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00438049 |
| (20MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00437999 |
| (40 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP | 300 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00438030 |
| (40MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP | 300 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00438022 |
| (40MMOL/L)POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP | 300 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00438006 |
| 0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01931598 |
| 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01927531 |
| 5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP | 50 MG | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01924435 |
How much does ELECTROLYTES WITH CARBOHYDRATES cost around the world?
ELECTROLYTES WITH CARBOHYDRATES is listed on 2 national price registers Nexara tracks, across 3 pack listings published on 2 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Iceland | max wholesale | 2 | 2 | 02 Sep 2026 |
| Saudi Arabia | public | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.